Publications by authors named "Kara Rice"

Claim this Profile
E
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.
Richard Lafayette, James Tumlin, Roberta Fenoglio, Jessica Kaufeld, Miguel Ángel Pérez Valdivia, Kara Rice

J Am Soc Nephrol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.
Tobin J Cammett, Katherine Garlo, Ellen E Millman, Kara Rice, Catherine M Toste

Mol Diagn Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.
Tobin J Cammett, Katherine Garlo, Ellen E Millman, Kara Rice, Catherine M Toste

Mol Diagn Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Steven D Podos, Howard Trachtman, Gerald B Appel, Andrew S Bomback, Bradley P Dixon, Kara Rice

Am J Nephrol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Carla Nester, Gerald B Appel, Andrew S Bomback, Koenraad Peter Bouman, H Terence Cook, Kara Rice

Am J Nephrol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
Toshko Lissitchkov, Annemieke Willemze, Suresh Katragadda, Kara Rice, Stacey Poloskey

Blood Adv· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
Barbara A Konkle, Amy D Shapiro, Doris V Quon, Janice M Staber, Roshni Kulkarni, Kara Rice

N Engl J Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.
Amy S Paller, Elaine C Siegfried, David M Pariser, Kara Creamer Rice, Mona Trivedi

J Am Acad Dermatol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.
Alexa B Kimball, Kenneth J Rothman, Gregory Kricorian, David Pariser, Paul S Yamauchi, Kara Creamer Rice

J Am Acad Dermatol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis